Quizartinib Improves Survival in Patients with Relapsed Acute Myeloid Leukemia

FDA Expands Approval of Imbruvica® to Include Initial Treatment for Chronic Lymphocytic Leukemia & Small Cell Lymphoma

ASCO updated reports Calquence has "clinically meaningful" benefit in CLL and may avoid some BTK associated side effects

Venclexta Imbruvica or Rituxan combination therapy appears more promising than single agent treatment.

CLL patients are at increased risk of developing a new cancer including those taking Ibrutinib & BTK Inhibitors

Zydelig® combined with Treanda and Rituxan is and effective treatment of Chronic Lymphocytic Leukemia

CLL is treated with chemotherapy, precision medicines and most recently with CAR T, now with remissions of > 8 years.